Thrombolysis with tissue-type plasminogen activator (tPA) is the only FDA-approved pharmacological treatment of acute ischemic stroke (AIS), despite the increased risk of intracerebral hemorrhage. Here, PLAT is linked to intracerebral hemorrhage.